Revolution Medicines, Inc.RVMD

$162.99+5.22 (+3.31%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$32B

Large-cap

+2976%

2020 — today

10-Year Price

+466%

2020 — today

52-Week Range

$34.70$163.68

Current $162.99· 99%

Revolution Medicines is a clinical-stage precision oncology firm focused on novel pathways driving RAS-addicted cancers. Based in Redwood City, California, the company develops a pipeline of targeted inhibitors, including SHP2 inhibitor RMC-4630 (partnered with Sanofi), SOS1 inhibitor RMC-5845, and mTORC1 inhibitor RMC-5552. Its research prioritizes active RAS(ON) variants, advancing candidates like RMC-6291 and RMC-6236, alongside programs targeting KRASG13C(ON) and KRASG12D(ON) mutations.

Valuation in context

P/E ratio

-22.9

N/A

Not meaningful — company is unprofitable

P/B ratio

21.5

Near historic high

Near historic highs — last 10 years

FCF Yield

-3.3%

Near historic high

Near historic highs — last 10 years

Free · No credit card needed

Get alerted when RVMD is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.